Bernstein SocGen Group analyst Jeffrey Walch reiterated an Underperform rating and $7.70 price target on Summit Therapeutics plc (NASDAQ: SMMT).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE